Contrast-enhanced ultrasonography with SonoVue after infliximab therapy in Crohn's disease
2006-01-01 Guidi, L; De Franco, A; De Vitis, I; Armuzzi, A; Semeraro, S; Roberto, I; Papa, A; Bock, E; Gasbarrini, G; Fedeli, G
The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe
2020-01-01 Armuzzi, A; Tarallo, M; Lucas, J; Bluff, D; Hoskin, B; Bargo, D; Cappelleri, Jc; Salese, L; daCosta DiBonaventura, M
Risk factors and timing for colectomy in chronically active refractory ulcerative colitis: A systematic review
2019-01-01 Macaluso, Fs; Cavallaro, F; Felice, C; Mazza, M; Armuzzi, A; Gionchetti, P; Vecchi, M; Orlando, A
Infliximab: A review of its use in the treatment of inflammatory Bowel disease
2011-01-01 Marzo, M; Felice, C; Rapaccini, Gl; Guidi, L; Armuzzi, A
The impact of COVID-19 pandemic on IBD endoscopic procedures in a high-volume IBD Center
2020-01-01 Lopetuso, Lr; Scaldaferri, F; Ianiro, G; Bibbò, S; Settanni, Cr; Papa, A; Armuzzi, A; Gasbarrini, A; Cammarota, G
Adalimumab in the treatment of immune-mediated diseases
2014-01-01 Lapadula, G; Marchesoni, A; Armuzzi, Alessandro; Blandizzi, C; Caporali, R; Chimenti, S; Cimaz, R; Cimino, L; Gionchetti, P; Girolomoni, G; Lionetti, P; Marcellusi, A; Mennini, Fs; Salvarani, C.
Role of sucralfate in gastrointestinal diseases
2000-01-01 Candelli, M; Carloni, E; Armuzzi, A; Cammarota, G; Ojetti, V; Pignataro, G; Santoliquido, A; Pola, R; Pola, E; Gasbarrini, G; Gasbarrini, A
Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus
2000-01-01 Gasbarrini, A; Ojetti, V; Pitocco, D; Armuzzi, A; Silveri, Ng; Pola, P; Ghirlanda, C; Gasbarrini, G
Association between Helicobacter pylori cytotoxic type I CagA-positive strains and migraine with aura
2000-01-01 Gasbarrini, A; Gabrielli, M; Fiore, G; Candelli, M; Bartolozzi, F; De Luca, A; Cremonini, F; Franceschi, F; Di Campli, C; Armuzzi, A; Ojetti, V; Serricchio, M; Pola, R; Gasbarrini, G; Giacovazzo, M; Pola, P
Implementing the Concept of Continuous Clinical Response Into Clinical Practice for Ulcerative Colitis
2017-01-01 Peyrin-Biroulet, L; Van Assche, G; Armuzzi, A; Garcia-Alvarez, L; Lara, N; Black, Cm; Khalifa, A; Cornillie, F; Kachroo, S
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis
2013-01-01 Andrisani, Gianluca; Gremese, Elisa; Guidi, Luisa; Papa, Alfredo; Marzo, Manuela; Felice, Carla; Pugliese, Daniela; Armuzzi, Alessandro
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients
2021-01-01 Pugliese, D; Guidi, L; Privitera, G; Bertani, L; Tolusso, B; Papparella, Lg; Maltinti, S; Di Mario, C; Onali, S; Ceccarelli, L; Rapaccini, Gl; Scaldaferri, F; Gremese, E; Gasbarrini, A; Costa, F; Armuzzi, A
Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease
2014-01-01 Rahier, Jf; Magro, F; Abreu, C; Armuzzi, Alessandro; Ben Horin, S; Chowers, Y; Cottone, M; De Ridder, L; Doherty, G; Ehehalt, R; Esteve, M; Katsanos, K; Lees, Cw; Macmahon, E; Moreels, T; Reinisch, W; Tilg, H; Tremblay, L; Veereman Wauters, G; Viget, N; Yazdanpanah, Y; Eliakim, R; Colombel, Jf
anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab
2014-01-01 Armuzzi, Alessandro; Lionetti, P; Blandizzi, C; Caporali, R; Chimenti, S; Cimino, L; Gionchetti, P; Girolomoni, G; Lapadula, G; Marchesoni, A; Marcellusi, A; Mennini, Fs; Salvarani, C; Cimaz, R.
Role of HMGB1 as a suitable biomarker of subclinical intestinal inflammation and mucosal healing in patients with inflammatory bowel disease
2014-01-01 Palone, F; Vitali, R; Cucchiara, S; Pierdomenico, M; Negroni, A; Aloi, M; Nuti, F; Felice, C; Armuzzi, Alessandro; Stronati, L.
Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel disease: histological and immunological features of a complex synovitis
2018-01-01 Alivernini, S; Pugliese, D; Tolusso, B; Bui, L; Petricca, L; Guidi, L; Mirone, L; Rapaccini, Gl; Federico, F; Ferraccioli, G; Armuzzi, A; Gremese, E
Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient Management
2021-01-01 Sands, Be; Colombel, Jf; Ha, C; Farnier, M; Armuzzi, A; Quirk, D; Friedman, Gs; Kwok, K; Salese, L; Su, C; Taub, Pr
Update on the management of inflammatory bowel disease: specific role of adalimumab
2011-01-01 Guidi, L; Pugliese, D; Armuzzi, A
Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study
2021-01-01 Festa, S; Scribano, Ml; Pugliese, D; Bezzio, C; Principi, M; Ribaldone, Dg; Allocca, M; Mocci, G; Bodini, G; Spagnuolo, R; Vernia, P; Mazzuoli, S; Costa, F; Barberio, B; Cosintino, R; Zerboni, G; Aratari, A; Armuzzi, A; Papi, C
Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients
2013-01-01 Andrisani, Gianluca; Armuzzi, Alessandro; Papa, Alfredo; Marzo, Manuela; Felice, Carla; Pugliese, Daniela; De Vitis, Italo; Rapaccini, Gian Ludovico; Guidi, Luisa
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Contrast-enhanced ultrasonography with SonoVue after infliximab therapy in Crohn's disease | 1-gen-2006 | Guidi, L; De Franco, A; De Vitis, I; Armuzzi, A; Semeraro, S; Roberto, I; Papa, A; Bock, E; Gasbarrini, G; Fedeli, G | |
| The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe | 1-gen-2020 | Armuzzi, A; Tarallo, M; Lucas, J; Bluff, D; Hoskin, B; Bargo, D; Cappelleri, Jc; Salese, L; daCosta DiBonaventura, M | |
| Risk factors and timing for colectomy in chronically active refractory ulcerative colitis: A systematic review | 1-gen-2019 | Macaluso, Fs; Cavallaro, F; Felice, C; Mazza, M; Armuzzi, A; Gionchetti, P; Vecchi, M; Orlando, A | |
| Infliximab: A review of its use in the treatment of inflammatory Bowel disease | 1-gen-2011 | Marzo, M; Felice, C; Rapaccini, Gl; Guidi, L; Armuzzi, A | |
| The impact of COVID-19 pandemic on IBD endoscopic procedures in a high-volume IBD Center | 1-gen-2020 | Lopetuso, Lr; Scaldaferri, F; Ianiro, G; Bibbò, S; Settanni, Cr; Papa, A; Armuzzi, A; Gasbarrini, A; Cammarota, G | |
| Adalimumab in the treatment of immune-mediated diseases | 1-gen-2014 | Lapadula, G; Marchesoni, A; Armuzzi, Alessandro; Blandizzi, C; Caporali, R; Chimenti, S; Cimaz, R; Cimino, L; Gionchetti, P; Girolomoni, G; Lionetti, P; Marcellusi, A; Mennini, Fs; Salvarani, C. | |
| Role of sucralfate in gastrointestinal diseases | 1-gen-2000 | Candelli, M; Carloni, E; Armuzzi, A; Cammarota, G; Ojetti, V; Pignataro, G; Santoliquido, A; Pola, R; Pola, E; Gasbarrini, G; Gasbarrini, A | |
| Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus | 1-gen-2000 | Gasbarrini, A; Ojetti, V; Pitocco, D; Armuzzi, A; Silveri, Ng; Pola, P; Ghirlanda, C; Gasbarrini, G | |
| Association between Helicobacter pylori cytotoxic type I CagA-positive strains and migraine with aura | 1-gen-2000 | Gasbarrini, A; Gabrielli, M; Fiore, G; Candelli, M; Bartolozzi, F; De Luca, A; Cremonini, F; Franceschi, F; Di Campli, C; Armuzzi, A; Ojetti, V; Serricchio, M; Pola, R; Gasbarrini, G; Giacovazzo, M; Pola, P | |
| Implementing the Concept of Continuous Clinical Response Into Clinical Practice for Ulcerative Colitis | 1-gen-2017 | Peyrin-Biroulet, L; Van Assche, G; Armuzzi, A; Garcia-Alvarez, L; Lara, N; Black, Cm; Khalifa, A; Cornillie, F; Kachroo, S | |
| Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis | 1-gen-2013 | Andrisani, Gianluca; Gremese, Elisa; Guidi, Luisa; Papa, Alfredo; Marzo, Manuela; Felice, Carla; Pugliese, Daniela; Armuzzi, Alessandro | |
| Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients | 1-gen-2021 | Pugliese, D; Guidi, L; Privitera, G; Bertani, L; Tolusso, B; Papparella, Lg; Maltinti, S; Di Mario, C; Onali, S; Ceccarelli, L; Rapaccini, Gl; Scaldaferri, F; Gremese, E; Gasbarrini, A; Costa, F; Armuzzi, A | |
| Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease | 1-gen-2014 | Rahier, Jf; Magro, F; Abreu, C; Armuzzi, Alessandro; Ben Horin, S; Chowers, Y; Cottone, M; De Ridder, L; Doherty, G; Ehehalt, R; Esteve, M; Katsanos, K; Lees, Cw; Macmahon, E; Moreels, T; Reinisch, W; Tilg, H; Tremblay, L; Veereman Wauters, G; Viget, N; Yazdanpanah, Y; Eliakim, R; Colombel, Jf | |
| anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab | 1-gen-2014 | Armuzzi, Alessandro; Lionetti, P; Blandizzi, C; Caporali, R; Chimenti, S; Cimino, L; Gionchetti, P; Girolomoni, G; Lapadula, G; Marchesoni, A; Marcellusi, A; Mennini, Fs; Salvarani, C; Cimaz, R. | |
| Role of HMGB1 as a suitable biomarker of subclinical intestinal inflammation and mucosal healing in patients with inflammatory bowel disease | 1-gen-2014 | Palone, F; Vitali, R; Cucchiara, S; Pierdomenico, M; Negroni, A; Aloi, M; Nuti, F; Felice, C; Armuzzi, Alessandro; Stronati, L. | |
| Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel disease: histological and immunological features of a complex synovitis | 1-gen-2018 | Alivernini, S; Pugliese, D; Tolusso, B; Bui, L; Petricca, L; Guidi, L; Mirone, L; Rapaccini, Gl; Federico, F; Ferraccioli, G; Armuzzi, A; Gremese, E | |
| Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient Management | 1-gen-2021 | Sands, Be; Colombel, Jf; Ha, C; Farnier, M; Armuzzi, A; Quirk, D; Friedman, Gs; Kwok, K; Salese, L; Su, C; Taub, Pr | |
| Update on the management of inflammatory bowel disease: specific role of adalimumab | 1-gen-2011 | Guidi, L; Pugliese, D; Armuzzi, A | |
| Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study | 1-gen-2021 | Festa, S; Scribano, Ml; Pugliese, D; Bezzio, C; Principi, M; Ribaldone, Dg; Allocca, M; Mocci, G; Bodini, G; Spagnuolo, R; Vernia, P; Mazzuoli, S; Costa, F; Barberio, B; Cosintino, R; Zerboni, G; Aratari, A; Armuzzi, A; Papi, C | |
| Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients | 1-gen-2013 | Andrisani, Gianluca; Armuzzi, Alessandro; Papa, Alfredo; Marzo, Manuela; Felice, Carla; Pugliese, Daniela; De Vitis, Italo; Rapaccini, Gian Ludovico; Guidi, Luisa |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Scopri
Tipologia
- 1 Contributo su Rivista27918
Data di pubblicazione
- In corso di stampa14
- 2020 - 20269653
- 2010 - 201911835
- 2000 - 20094579
- 1990 - 19991485
- 1980 - 1989329
- 1975 - 197923
Editore
- Edition AERCV1
- Elsevier1
- Futura Publishing Company1
- Grafica Luigi Monti s.r.l.1
- Karger, Basel1
- Mosby1
- sn1
- Springer-Verlag1
- Thieme1
Rivista
- DIGESTIVE AND LIVER DISEASE372
- EUROPEAN JOURNAL OF NUCLEAR MEDIC...267
- ANNALS OF ONCOLOGY244
- CANCERS232
- PLOS ONE223
- THE JOURNAL OF NUCLEAR MEDICINE222
- JOURNAL OF CLINICAL MEDICINE215
- EUROPEAN JOURNAL OF CANCER205
- GASTROINTESTINAL ENDOSCOPY197
- ALLERGY180
Keyword
- Humans2166
- Female1035
- Male996
- Middle Aged767
- Aged669
- Adult559
- COVID-19442
- Treatment Outcome373
- Animals329
- Retrospective Studies264
Lingua
- eng19972
- ita459
- spa14
- fre11
- ger8
- enm4
- por2
- chi1
Accesso al fulltext
- no fulltext25665
- reserved1362
- open891